Morepen Laboratories Limited (MOREPENLAB) Price & Analysis

Compare

4 Followers

MOREPENLAB Stock Chart & Stats

Day’s Range― - ―

52-Week Range₹41.66 - ₹100.80

Previous CloseN/A

Volume3.34M

Average Volume (3M)367.00K

Market Cap

₹25.92B

Enterprise Value₹44.33B

Total Cash (Recent Filing)₹1.27B

Total Debt (Recent Filing)₹1.05B

Price to Earnings (P/E)27.8

Beta1.85

Next Earnings

Nov 17, 2025

EPS EstimateN/A

Last Dividend Ex-Date

Aug 29, 2025

Dividend YieldN/A

Share Statistics

EPS (TTM)0.20

Shares Outstanding547,953,700

10 Day Avg. Volume335,469

30 Day Avg. Volume366,999

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

₹67.00

Price Target Upside41.62% Upside

Rating ConsensusHold

Number of Analyst Covering1

Morepen Laboratories Limited News

Morepen Laboratories Secures Loratadine Export Approval to China

Morepen Laboratories Limited ( ($IN:MOREPENLAB) ) just unveiled an update. Morepen Laboratories Limited has secured approval from China’s...

5M ago

MOREPENLAB FAQ

What was Morepen Laboratories Limited’s price range in the past 12 months?

Morepen Laboratories Limited lowest stock price was ₹41.66 and its highest was ₹100.80 in the past 12 months.

What is Morepen Laboratories Limited’s market cap?

Morepen Laboratories Limited’s market cap is ₹25.92B.

When is Morepen Laboratories Limited’s upcoming earnings report date?

Morepen Laboratories Limited’s upcoming earnings report date is Nov 17, 2025 which is in 80 days.

How were Morepen Laboratories Limited’s earnings last quarter?

Morepen Laboratories Limited released its earnings results on Aug 06, 2025. The company reported ₹0.196 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.196.

Is Morepen Laboratories Limited overvalued?

According to Wall Street analysts Morepen Laboratories Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Morepen Laboratories Limited pay dividends?

Morepen Laboratories Limited pays a Annually dividend of ₹0.2 which represents an annual dividend yield of N/A. See more information on Morepen Laboratories Limited dividends here

What is Morepen Laboratories Limited’s EPS estimate?

Morepen Laboratories Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Morepen Laboratories Limited have?

Morepen Laboratories Limited has 547,953,700 shares outstanding.

What happened to Morepen Laboratories Limited’s price movement after its last earnings report?

Morepen Laboratories Limited reported an EPS of ₹0.196 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -5.852%.

Which hedge fund is a major shareholder of Morepen Laboratories Limited?

Currently, no hedge funds are holding shares in IN:MOREPENLAB

Company Description

Morepen Laboratories Limited

Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), branded and generic formulations, and home health products in India. The company offers APIs for anti-histaminic, anti-asthmatic, anti-hypercholesterolemic, anti-hypertensive, and anti-diabetic drugs; point of care and medical devices; and home diagnostic products, such as air purifiers, thermometers, stethoscopes, blood pressure monitors, pulse-oximeters, nebulizers, glucometers, strips, sanitizers, disinfectant solutions, masks and gloves, and others. It also provides Burnol, a burn cream; Lemolate for cough and cold; and Fiber-X, a sat isabgol; and formulations for gastro, antibiotics, vitamins, nutritional, and anti-diabetics, as well as cardiac. In addition, the company is involved in the product contract manufacturing and brand sharing businesses; and provision of over-the-counter products under the Dr. Morepen brand. It exports its products to approximately 75 countries. Morepen Laboratories Limited was incorporated in 1984 and is based in New Delhi, India.

Morepen Laboratories Limited (MOREPENLAB) Earnings & Revenues

Historic Earnings Reports

MOREPENLAB Stock 12 Month Forecast

Average Price Target

₹67.00

▲(41.62% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"45":"₹45","88":"₹88","55.75":"₹55.8","66.5":"₹66.5","77.25":"₹77.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹67.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹67.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹67.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[45,55.75,66.5,77.25,88],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,62.07,62.449230769230766,62.82846153846154,63.207692307692305,63.58692307692308,63.966153846153844,64.34538461538462,64.72461538461539,65.10384615384615,65.48307692307692,65.8623076923077,66.24153846153847,66.62076923076923,{"y":67,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,62.07,62.449230769230766,62.82846153846154,63.207692307692305,63.58692307692308,63.966153846153844,64.34538461538462,64.72461538461539,65.10384615384615,65.48307692307692,65.8623076923077,66.24153846153847,66.62076923076923,{"y":67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,62.07,62.449230769230766,62.82846153846154,63.207692307692305,63.58692307692308,63.966153846153844,64.34538461538462,64.72461538461539,65.10384615384615,65.48307692307692,65.8623076923077,66.24153846153847,66.62076923076923,{"y":67,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":59.86,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":81.59,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":87.72,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":79.9,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":84.01,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":79.25,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":65.02,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":46.41,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":49.36,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":60.32,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":64.82,"date":1748736000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":62.07,"date":1751328000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":62.07,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >